FDA Approves Targeted Therapy for FGFR2-Altered Cholangiocarcinoma
The U.S. Food and Drug Administration has approved lirafugratinib (Lyrfigtu) for patients with advanced bile duct cancer that has an FGFR2 fusion or rearrangement, after prior treatment.
This approval marks a new option for patients with advanced bile duct cancer whose tumors harbor specific FGFR2 genetic alterations. The therapy is intended for those who have already received prior treatment, addressing an unmet need in a disease with limited late-line options. FGFR2 fusions or rearrangements are relatively uncommon but define a molecularly distinct subset of cholangiocarcinoma.
The decision follows a targeted-therapy development pathway, where biomarker-driven patient selection is central. By focusing on a specific genetic change, the drug offers a precision medicine approach rather than a broad chemotherapy regimen. This adds to a growing class of FGFR inhibitors, though the approval is specific to this agent and indication.
This approval could expand treatment choices for a niche but previously underserved patient group, potentially improving outcomes or extending survival in later-line settings. It may also encourage broader genetic testing among bile duct cancer patients, as identifying FGFR2 alterations becomes clinically actionable. However, its real-world impact depends on accessibility, tolerability, and how it compares with existing therapies—factors that will emerge through clinical use and further study.